The Role of Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Metastases from Breast Cancer: A Comprehensive Review and Pooled Individual-Patient Analysis
Die Rolle von zytoreduktiver Chirurgie plus hyperthermischer intraperitonealer Chemotherapie (HIPEC) bei Peritonealmetastasen des Mammakarzinoms: umfassende Übersicht und gepoolte Analyse von Individualpatientendaten
Journal of Clinical Medicine · 11.06.2026 · 15 (12) · 4511
DOI: 10.3390/jcm15124511 ↗Auf einen Blick
Sechs Studien mit 66 Patient:innen mit PMBC wurden zusammengefasst. CRS plus HIPEC erschien bei ausgewählten Patient:innen machbar; die berichteten Outcomes waren heterogen.
Fragestellung
Wie machbar, sicher und onkologisch wirksam ist CRS plus HIPEC bei Peritonealmetastasen des Mammakarzinoms?
Methode
PRISMA-orientierte narrative Übersichtsarbeit mit strukturierter Suche in PubMed/MEDLINE, Embase und Google Scholar bis 31. Dezember 2025; deskriptive gepoolte IPD-Analyse.
Ergebnisse
6 Studien mit 66 PMBC-Patient:innen; 30 erhielten CRS plus HIPEC. IPD-Analyse bei 17 Patient:innen aus 5 Studien. CC-0 bei 9/17; major morbidity 17,6 %; keine In-hospital- oder 30-Tage-Mortalität.
Einschränkungen
Kleine, heterogene Datenbasis; starke Anfälligkeit für Selektions- und Publikationsbias; keine inferenzielle Überlebensanalyse.
Schlussfolgerung der Autor:innen
CRS plus HIPEC erscheint bei hoch selektierten PMBC-Patient:innen machbar und könnte bei kompletter Zytoreduktion günstig sein; der unabhängige Nutzen von HIPEC ist nicht belegt.
Kernaussagen
- CRS plus HIPEC wurde bei 30 von 66 Patient:innen eingesetzt
- CC-0 wurde bei 9/17 Patient:innen erreicht
- Keine In-hospital- oder 30-Tage-Mortalität berichtet
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 11.06.2026. Verfasst von Dimitrios Papageorgiou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Athens Naval and Veterans Hospital, 11521 Athens, Greece. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/Objectives: Peritoneal metastases from breast cancer (PMBC) are rare, aggressive, and lack standardized management. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a potential locoregional strategy for highly selected patients. This PRISMA-informed narrative review used a structured and reproducible search and study-selection process, SWiM-guided narrative synthesis, and descriptive pooled individual-patient data (IPD) analysis to evaluate the feasibility, safety, and reported oncologic outcomes of CRS plus HIPEC in PMBC.
Methods
The English-language literature was searched in PubMed/MEDLINE, Embase, and Google Scholar up to 31 December 2025. Eligible peer-reviewed full-text articles reported PMBC patients treated with CRS plus HIPEC and at least one perioperative or oncologic outcome. Patient-level data were extracted when explicitly reported and were summarized descriptively; no inferential survival analysis was performed. Risk of bias was assessed using JBI checklists for case reports/series and ROBINS-I for the multicenter cohort.
Results
Six peer-reviewed studies were included (66 PMBC patients); 30 patients underwent CRS plus HIPEC. Five studies provided sufficient patient-level data for descriptive pooled IPD analysis (n = 17). Median age at CRS/HIPEC was 56 years (n = 13 with reported age), and the median interval between breast cancer diagnosis and PMBC was 12 years (range 0–30 years; available-case analysis). Median PCI was 21.5 (n = 16), and complete cytoreduction (CC-0) was achieved in 9 of 17 patients. Major postoperative morbidity occurred in 17.6%, while no in-hospital or 30-day mortality was reported. Reported disease-control and survival outcomes were heterogeneous and are therefore summarized only descriptively. In the multicenter cohort, curative-intent CRS with or without HIPEC was associated with a median overall survival of 61.5 months measured from diagnosis of peritoneal metastases; however, HIPEC-specific baseline characteristics and oncologic outcomes were not separately stratified.
Conclusions
CRS plus HIPEC appears feasible in highly selected PMBC patients and may be associated with favorable outcomes when complete cytoreduction is achievable. However, the evidence is sparse, heterogeneous, and highly prone to selection and publication bias. Therefore, no causal inference regarding the independent benefit of HIPEC can be drawn, and this approach should be considered investigational pending prospective multicenter registries.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecology, Athens Naval and Veterans Hospital, 11521 Athens, Greece.
- Department of Surgery, Athens Naval and Veterans Hospital, 11521 Athens, Greece.
- 1st Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, 10679 Athens, Greece.
- Laboratory of Anatomy, Faculty of Nursing, National and Kapodistrian University of Athens, 11527 Athens, Greece.
ORCID-Profile: Dimitrios Papageorgiou, Vasileios Kalles, Vasilios Pergialiotis, Ioannis K Papapanagiotou, Nikolaos Tasis, Katerina Papakonstantinou, Ioakeim Sapantzoglou
Zitieren
APA
Papageorgiou, D., Kalles, V., Pergialiotis, V., Papapanagiotou, I. K., Tasis, N., Petrogiannis, S., Papakonstantinou, K., & Sapantzoglou, I. (2026). The Role of Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Metastases from Breast Cancer: A Comprehensive Review and Pooled Individual-Patient Analysis. Journal of Clinical Medicine, 15(12), 4511. https://doi.org/10.3390/jcm15124511
Vancouver
Papageorgiou D, Kalles V, Pergialiotis V, Papapanagiotou IK, Tasis N, Petrogiannis S, et al. The Role of Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Metastases from Breast Cancer: A Comprehensive Review and Pooled Individual-Patient Analysis. Journal of Clinical Medicine. 2026;15(12):4511. doi:10.3390/jcm15124511
BibTeX
@article{Papageorgiou2026,
author = {Papageorgiou, Dimitrios and Kalles, Vasileios and Pergialiotis, Vasilios and Papapanagiotou, Ioannis K and Tasis, Nikolaos and Petrogiannis, Savvas and Papakonstantinou, Katerina and Sapantzoglou, Ioakeim},
title = {The Role of Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Metastases from Breast Cancer: A Comprehensive Review and Pooled Individual-Patient Analysis},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {12},
pages = {4511},
doi = {10.3390/jcm15124511}
}
EUVIMED